Enzymatica AB: Enzymatica signs agreement for ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa
31 Luglio 2018 - 1:00PM
Press release
Lund July 31, 2018
Enzymatica signs agreement for
ColdZyme with ABEX Pharmaceutica (Pty) Ltd for South Africa
Enzymatica has entered into a
distribution agreement with ABEX for marketing and sales of
ColdZyme® cold spray on the South African market. The product will
be launched into the market in late 2018.
ABEX will sell ColdZyme to all major pharmacy
chains, independent pharmacies, as well as through non-conventional
channels and grocery stores in South Africa. The company plans to
launch ColdZyme in late 2018, but with a focus on the 2019 South
African winter season, which extends from March to July. The
company will conduct an extensive marketing campaign, including
advertising in traditional media and in-store advertising, as well
as radio commercials and marketing in social media.
The South African cold market is estimated at ZAR
2.1 billion, corresponding to about SEK 1.4 billion. Most cold
preparations provide symptomatic relief and only a few cold sprays
focus on the cold virus. Consequently, ABEX sees great
opportunities to position ColdZyme as an extremely interesting
treatment option within the segment.
"We
are extremely proud of our collaboration with Enzymatica and the
opportunity to be responsible for introducing ColdZyme to the
market. With the lack of new clinically proven treatment options in
the local market, there is huge potential for ColdZyme to become a
trusted household brand for consumers, which can be used both as a
preventative option as well as to reduce the duration of colds,"
says Ed Hallam, who is responsible for commercial operations at
ABEX.
"We
are extremely pleased about the agreement with ABEX, which is a
well-established and highly respected pharmaceutical company with a
strong distribution network in the South African market," says
Fredrik Lindberg, CEO of Enzymatica.
ABEX Pharmaceutica is a privately owned
pharmaceutical company that was founded in 2006 and has its
headquarters in Port Elizabeth, along with sales and technology
offices in Pretoria. The company also has representation offices in
China, Hong Kong, Australia and the United Kingdom. ABEX develops,
manufactures and sells both pharmaceuticals and over the counter
(OTC) products, as well as medical devices. The company has a total
of about 30 direct and indirect employees.
For
more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
Carl-Johan Wachtmeister, Head of Corporate Communications,
Enzymatica AB
Tel: +46 (0)701-88 50 21 | Email:
carl-johan.wachtmeister@enzymatica.com
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and
sells medical devices for infection-related diseases. The products
are based on a barrier technology that includes marine enzymes. The
company's first product is ColdZyme® Mouth Spray, which can prevent
colds and reduce the duration of disease. The product has been
launched in about ten markets. The strategy is to continue to grow
by strengthening the Company's position in existing markets and
expanding into new geographic markets through established partners.
The company has its headquarters in Lund and is listed on Nasdaq
First North. For more information,
visit: www.enzymatica.com
Enzymatica's certified adviser is Erik Penser Bank.För mer information, kontakta:
Enzymaticas Certified Adviser är Erik Penser
Bank.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
Grafico Azioni ENZYMOTEC LTD. (NASDAQ:ENZY)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni ENZYMOTEC LTD. (NASDAQ:ENZY)
Storico
Da Set 2023 a Set 2024